IL6 and rheumatoid arthritis: The probability to die also decreased statistically for patients enrolled in the TOCIVID-19 clinical trial (EudraCT Number: 2020-001110-38) [11], who received the biological therapy tocilizumab (RoActemra®), an immunosuppressive drug belonging to the class of drugs known as Interleukin-6 blockers, commonly used to treat adults with moderate to severe rheumatoid arthritis.